Hematologic Oncology

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

TERN-701 yielded a high response rate with deep molecular responses in patients with heavily pretreated chronic phase chronic myeloid leukemia.

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

The FDA has accepted and granted priority review to the sBLA for nivolumab plus AVD in untreated adult and pediatric classical Hodgkin lymphoma.

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.

Long-term follow-up data from the AGAVE-201 trial showed that safety and survival outcomes with axatilimab were maintained in patients with chronic GVHD.

The FDA has approved the HSCT therapy for patients 6 years or older with SAA following reduced-intensity conditioning who do not have a compatible donor.

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Adding epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in patients with relapsed/refractory follicular lymphoma.

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.

Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.